A	O
novel	O
T-cell	B-protein
protein	I-protein
which	O
recognizes	O
a	O
palindromic	B-DNA
sequence	I-DNA
in	O
the	O
negative	B-DNA
regulatory	I-DNA
element	I-DNA
of	O
the	O
human	B-DNA
immunodeficiency	I-DNA
virus	I-DNA
long	I-DNA
terminal	I-DNA
repeat	I-DNA
.	O

Two	O
major	B-DNA
protein-binding	I-DNA
sites	I-DNA
within	O
the	O
negative	B-DNA
regulatory	I-DNA
element	I-DNA
of	O
the	O
human	B-DNA
immunodeficiency	I-DNA
virus	I-DNA
type	I-DNA
1	I-DNA
long	I-DNA
terminal	I-DNA
repeat	I-DNA
have	O
been	O
identified	O
.	O

One	O
(	O
site	B-DNA
B	I-DNA
)	O
contained	O
a	O
palindromic	B-DNA
sequence	I-DNA
with	O
homology	O
to	O
steroid/thyroid	B-DNA
hormone	I-DNA
response	I-DNA
elements	I-DNA
but	O
was	O
distinct	O
from	O
previously	O
described	O
binding	O
sites	O
of	O
this	O
class	O
.	O

A	O
novel	O
T-cell	B-protein
protein	I-protein
recognized	O
the	O
palindromic	B-DNA
sequence	I-DNA
within	O
site	B-DNA
B	I-DNA
and	O
also	O
bound	O
estrogen-	B-DNA
or	I-DNA
thyroid	I-DNA
hormone-response	I-DNA
elements	I-DNA
with	O
lower	O
affinity	O
.	O

A	O
7-base-pair	O
mutation	O
in	O
the	O
site	B-DNA
B	I-DNA
palindrome	I-DNA
,	O
which	O
destroyed	O
protein	O
binding	O
,	O
resulted	O
in	O
increased	O
expression	O
from	O
the	O
human	B-DNA
immunodeficiency	I-DNA
virus	I-DNA
type	I-DNA
1	I-DNA
long	I-DNA
terminal	I-DNA
repeat	I-DNA
in	O
T	B-cell_type
cells	I-cell_type
.	O

JOURNAL	NULL
OF	NULL
ViroLOGY	NULL
,	NULL
July	NULL
1990	NULL
,	NULL
p.	NULL
3234-3239	NULL
0022-538	NULL
X/90/073234-06	NULL
$	NULL
02.00/0	NULL
Copyright	NULL
Â©	NULL
1990	NULL
,	NULL
American	NULL
Society	NULL
for	NULL
Microbiology	NULL
Vol	NULL
.	NULL

64	NULL
,	NULL
No	NULL
.	NULL

7	NULL
A	NULL
Novel	NULL
T-Cell	NULL
Protein	NULL
Which	NULL
Recognizes	NULL
a	NULL
Palindromic	NULL
Sequence	NULL
in	NULL
the	NULL
Negative	NULL
Regulatory	NULL
Element	NULL
of	NULL
the	NULL
Human	NULL
Immunodeficiency	NULL
Virus	NULL
Long	NULL
Terminal	NULL
Repeat	NULL
KIM	NULL
ORCHARD	NULL
,	NULL
*	NULL
?	NULL

NEIL	NULL
PERKINS	NULL
,	NULL
``	NULL
CAROLINE	NULL
CHAPMAN	NULL
,	NULL
``	NULL
JULIAN	NULL
HARRIS	NULL
,	NULL
``	NULL
VINCENT	NULL
EMERY	NULL
,	NULL
``	NULL
GRAHAM	NULL
GOODWIN	NULL
,	NULL
``	NULL
DAVID	NULL
LATCHMAN	NULL
,	NULL
*	NULL
anp	NULL
MARY	NULL
COLLINS'*	NULL
Institute	NULL
of	NULL
Cancer	NULL
Research	NULL
,	NULL
Chester	NULL
Beatty	NULL
Laboratories	NULL
,	NULL
237	NULL
Fulham	NULL
Road	NULL
,	NULL
London	NULL
SW3	NULL
6JB	NULL
,	NULL
'	NULL
Department	NULL
of	NULL
Virology	NULL
,	NULL
Royal	NULL
Free	NULL
Hospital	NULL
School	NULL
of	NULL
Medicine	NULL
,	NULL
Pond	NULL
Street	NULL
,	NULL
London	NULL
NW3	NULL
20G	NULL
,	NULL
*	NULL
and	NULL
Medical	NULL
Molecular	NULL
Biology	NULL
Unit	NULL
,	NULL
Department	NULL
of	NULL
Biochemistry	NULL
,	NULL
The	NULL
Windeyer	NULL
Building	NULL
,	NULL
University	NULL
College	NULL
and	NULL
Middlesex	NULL
School	NULL
of	NULL
Medicine	NULL
,	NULL
London	NULL
WIP	NULL
6DB	NULL
,	NULL
``	NULL
England	NULL
Received	NULL
1	NULL
November	NULL
1989/Accepted	NULL
20	NULL
March	NULL
1990	NULL
Two	NULL
major	NULL
protein-binding	NULL
sites	NULL
within	NULL
the	NULL
negative	NULL
regulatory	NULL
element	NULL
of	NULL
the	NULL
human	NULL
immunodeficiency	NULL
virus	NULL
type	NULL
1	NULL
long	NULL
terminal	NULL
repeat	NULL
have	NULL
been	NULL
identified	NULL
.	NULL

One	NULL
(	NULL
site	NULL
B	NULL
)	NULL
contained	NULL
a	NULL
palindromic	NULL
sequence	NULL
with	NULL
homology	NULL
to	NULL
steroid/thyroid	NULL
hormone	NULL
response	NULL
elements	NULL
but	NULL
was	NULL
distinct	NULL
from	NULL
previously	NULL
described	NULL
binding	NULL
sites	NULL
of	NULL
this	NULL
class	NULL
.	NULL

A	NULL
novel	NULL
T-cell	NULL
protein	NULL
recognized	NULL
the	NULL
palindromic	NULL
sequence	NULL
within	NULL
site	NULL
B	NULL
and	NULL
also	NULL
bound	NULL
estrogen-	NULL
or	NULL
thyroid	NULL
hormone-response	NULL
elements	NULL
with	NULL
lower	NULL
affinity	NULL
.	NULL

A	NULL
7-base-pair	NULL
mutation	NULL
in	NULL
the	NULL
site	NULL
B	NULL
palindrome	NULL
,	NULL
which	NULL
destroyed	NULL
protein	NULL
binding	NULL
,	NULL
resulted	NULL
in	NULL
increased	NULL
expression	NULL
from	NULL
the	NULL
human	NULL
immunodefi-	NULL
ciency	NULL
virus	NULL
type	NULL
1	NULL
long	NULL
terminal	NULL
repeat	NULL
in	NULL
T	NULL
cells	NULL
.	NULL

Expression	NULL
from	NULL
the	NULL
human	NULL
immunodeficiency	NULL
virus	NULL
type	NULL
1	NULL
(	NULL
HIV-1	NULL
)	NULL
long	NULL
terminal	NULL
repeat	NULL
(	NULL
LTR	NULL
)	NULL
is	NULL
known	NULL
to	NULL
be	NULL
regulated	NULL
by	NULL
host	NULL
cell	NULL
parameters	NULL
,	NULL
such	NULL
as	NULL
T-lymphocyte	NULL
activation	NULL
(	NULL
2	NULL
,	NULL
13	NULL
,	NULL
18	NULL
)	NULL
,	NULL
lymphokine	NULL
action	NULL
(	NULL
10	NULL
,	NULL
14	NULL
)	NULL
,	NULL
and	NULL
macrophage	NULL
differentiation	NULL
(	NULL
8	NULL
)	NULL
.	NULL

These	NULL
events	NULL
have	NULL
the	NULL
potential	NULL
to	NULL
influence	NULL
critically	NULL
the	NULL
progress	NULL
of	NULL
disease	NULL
in	NULL
infected	NULL
individuals	NULL
.	NULL

A	NULL
number	NULL
of	NULL
cellular	NULL
proteins	NULL
capable	NULL
of	NULL
binding	NULL
to	NULL
the	NULL
HIV-1	NULL
LTR	NULL
have	NULL
been	NULL
identified	NULL
(	NULL
2	NULL
,	NULL
4	NULL
,	NULL
5	NULL
,	NULL
13	NULL
,	NULL
18	NULL
,	NULL
20	NULL
)	NULL
,	NULL
and	NULL
one	NULL
of	NULL
these	NULL
,	NULL
NFxB	NULL
,	NULL
binds	NULL
to	NULL
the	NULL
enhancer	NULL
region	NULL
of	NULL
the	NULL
LTR	NULL
and	NULL
increases	NULL
viral	NULL
transcription	NULL
in	NULL
response	NULL
to	NULL
several	NULL
stimuli	NULL
(	NULL
10	NULL
,	NULL
13	NULL
,	NULL
14	NULL
)	NULL
.	NULL

In	NULL
contrast	NULL
,	NULL
however	NULL
,	NULL
the	NULL
region	NULL
of	NULL
the	NULL
LTR	NULL
upstream	NULL
of	NULL
base	NULL
-278	NULL
(	NULL
relative	NULL
to	NULL
the	NULL
start	NULL
of	NULL
transcription	NULL
)	NULL
has	NULL
been	NULL
identified	NULL
as	NULL
a	NULL
negative	NULL
regulatory	NULL
element	NULL
(	NULL
NRE	NULL
)	NULL
,	NULL
the	NULL
removal	NULL
of	NULL
which	NULL
increases	NULL
LTR	NULL
expression	NULL
in	NULL
the	NULL
Jurkat	NULL
T-cell	NULL
line	NULL
(	NULL
19	NULL
)	NULL
.	NULL

A	NULL
partial	NULL
reconstitution	NULL
of	NULL
the	NULL
repressive	NULL
activity	NULL
is	NULL
observed	NULL
when	NULL
the	NULL
-340	NULL
to	NULL
-185	NULL
region	NULL
is	NULL
linked	NULL
to	NULL
a	NULL
heterologous	NULL
promoter	NULL
(	NULL
17	NULL
)	NULL
.	NULL

Furthermore	NULL
,	NULL
deletion	NULL
of	NULL
the	NULL
-419	NULL
to	NULL
-157	NULL
region	NULL
from	NULL
the	NULL
LTR	NULL
of	NULL
HIV-1	NULL
produces	NULL
a	NULL
mutant	NULL
which	NULL
replicates	NULL
more	NULL
rapidly	NULL
in	NULL
cell	NULL
culture	NULL
(	NULL
11	NULL
)	NULL
,	NULL
suggesting	NULL
that	NULL
this	NULL
region	NULL
plays	NULL
a	NULL
role	NULL
in	NULL
the	NULL
cellular	NULL
control	NULL
of	NULL
viral	NULL
replication	NULL
.	NULL

The	NULL
cellular	NULL
proteins	NULL
which	NULL
interact	NULL
with	NULL
the	NULL
NRE	NULL
are	NULL
therefore	NULL
clearly	NULL
of	NULL
interest	NULL
as	NULL
potential	NULL
transcriptional	NULL
repressors	NULL
.	NULL

Four	NULL
previous	NULL
reports	NULL
have	NULL
described	NULL
protein-binding	NULL
sites	NULL
within	NULL
the	NULL
-419	NULL
to	NULL
-157	NULL
region	NULL
(	NULL
4	NULL
,	NULL
5	NULL
,	NULL
18	NULL
,	NULL
20	NULL
)	NULL
,	NULL
although	NULL
their	NULL
importance	NULL
in	NULL
HIV-1	NULL
LTR	NULL
transcriptional	NULL
regulation	NULL
remains	NULL
to	NULL
be	NULL
characterized	NULL
.	NULL

Two	NULL
of	NULL
these	NULL
studies	NULL
identify	NULL
binding	NULL
sites	NULL
for	NULL
known	NULL
inducible	NULL
transcriptional	NULL
activators	NULL
of	NULL
cellular	NULL
genes	NULL
,	NULL
API	NULL
(	NULL
4	NULL
)	NULL
and	NULL
NFAT1	NULL
(	NULL
18	NULL
)	NULL
,	NULL
and	NULL
one	NULL
identifies	NULL
a	NULL
binding	NULL
site	NULL
for	NULL
a	NULL
repressor	NULL
of	NULL
interleukin-2	NULL
receptor	NULL
a-chain	NULL
transcription	NULL
(	NULL
20	NULL
)	NULL
.	NULL

This	NULL
suggests	NULL
a	NULL
potentially	NULL
complex	NULL
mechanism	NULL
of	NULL
regulation	NULL
,	NULL
involving	NULL
a	NULL
balance	NULL
between	NULL
positive	NULL
and	NULL
negative	NULL
cellular	NULL
factors	NULL
binding	NULL
to	NULL
this	NULL
region	NULL
.	NULL

In	NULL
this	NULL
report	NULL
we	NULL
describe	NULL
two	NULL
further	NULL
protein-binding	NULL
sites	NULL
within	NULL
the	NULL
HIV-1	NULL
LTR	NULL
NRE	NULL
which	NULL
are	NULL
*	NULL
Corresponding	NULL
author	NULL
.	NULL

3234	NULL
recognized	NULL
by	NULL
previously	NULL
undescribed	NULL
human	NULL
T-cell	NULL
pro-teins	NULL
.	NULL

We	NULL
have	NULL
characterized	NULL
one	NULL
of	NULL
these	NULL
proteins	NULL
as	NULL
related	NULL
in	NULL
binding	NULL
specificity	NULL
to	NULL
steroid/thyroid	NULL
hormone	NULL
receptors	NULL
and	NULL
have	NULL
demonstrated	NULL
that	NULL
it	NULL
acts	NULL
as	NULL
a	NULL
repressor	NULL
of	NULL
HIV-1	NULL
LTR-driven	NULL
gene	NULL
expression	NULL
in	NULL
T	NULL
cells	NULL
.	NULL

MATERIALS	NULL
AND	NULL
METHODS	NULL
DNase	NULL
I	NULL
footprint	NULL
analysis	NULL
.	NULL

The	NULL
NRE	NULL
fragment	NULL
was	NULL
a	NULL
Kpnl-to-Rsal	NULL
fragment	NULL
from	NULL
HIV-HXB2	NULL
subcloned	NULL
in	NULL
Kpnrl-Smal-digested	NULL
pUC13	NULL
and	NULL
then	NULL
labeled	NULL
on	NULL
the	NULL
bottom	NULL
strand	NULL
by	NULL
digestion	NULL
of	NULL
the	NULL
polylinker	NULL
with	NULL
HindIII	NULL
,	NULL
phosphatasing	NULL
,	NULL
kinasing	NULL
with	NULL
[	NULL
P	NULL
?	NULL

PJATP	NULL
,	NULL
redigestion	NULL
of	NULL
the	NULL
polylinker	NULL
with	NULL
EcoRI	NULL
,	NULL
and	NULL
gel	NULL
purification	NULL
.	NULL

Nuclear	NULL
extracts	NULL
were	NULL
prepared	NULL
as	NULL
described	NULL
previously	NULL
(	NULL
3	NULL
)	NULL
,	NULL
from	NULL
Jurkat	NULL
cells	NULL
activated	NULL
by	NULL
incubation	NULL
for	NULL
5	NULL
h	NULL
with	NULL
5	NULL
ug	NULL
of	NULL
phytohemagglutinin	NULL
per	NULL
ml	NULL
and	NULL
10	NULL
nM	NULL
phorbolmyristylacetate	NULL
,	NULL
except	NULL
that	NULL
the	NULL
cells	NULL
were	NULL
lysed	NULL
in	NULL
buffer	NULL
A	NULL
with	NULL
0.23	NULL
M	NULL
sucrose	NULL
.	NULL

Nuclei	NULL
were	NULL
then	NULL
pelleted	NULL
,	NULL
washed	NULL
once	NULL
in	NULL
the	NULL
same	NULL
buffer	NULL
,	NULL
and	NULL
then	NULL
lysed	NULL
in	NULL
buffer	NULL
C	NULL
containing	NULL
0.3	NULL
M	NULL
NaCl	NULL
.	NULL

Protease	NULL
and	NULL
phosphatase	NULL
inhibitors	NULL
were	NULL
present	NULL
in	NULL
all	NULL
buffers	NULL
(	NULL
15	NULL
)	NULL
.	NULL

Final	NULL
extract	NULL
protein	NULL
concentrations	NULL
were	NULL
between	NULL
6	NULL
and	NULL
10	NULL
mg/ml	NULL
.	NULL

DNase	NULL
I	NULL
footprinting	NULL
assays	NULL
(	NULL
16	NULL
)	NULL
used	NULL
2	NULL
ng	NULL
of	NULL
NRE	NULL
fragment	NULL
,	NULL
10	NULL
pmol	NULL
of	NULL
30-base-pair	NULL
competitor	NULL
oligonucleotide	NULL
(	NULL
sequence	NULL
-362	NULL
to	NULL
-383	NULL
[	NULL
site	NULL
A	NULL
]	NULL
and	NULL
-327	NULL
to	NULL
-358	NULL
[	NULL
site	NULL
BJ	NULL
)	NULL
,	NULL
and	NULL
5	NULL
pug	NULL
of	NULL
poly	NULL
(	NULL
dI	NULL
-	NULL
dC	NULL
)	NULL
(	NULL
Pharmacia	NULL
)	NULL
incubated	NULL
with	NULL
40	NULL
ug	NULL
of	NULL
Jurkat	NULL
extract	NULL
in	NULL
20	NULL
mM	NULL
HEPES	NULL
(	NULL
N-2-hydroxyethylpiperazine-N'-2-ethanesulfonic	NULL
acid	NULL
)	NULL
(	NULL
pH	NULL
7.9	NULL
)	NULL
,	NULL
2	NULL
mM	NULL
MgCl	NULL
,	NULL
,	NULL
50	NULL
mM	NULL
NaCl	NULL
,	NULL
1	NULL
mM	NULL
dithiothreitol	NULL
,	NULL
and	NULL
20	NULL
%	NULL
glycerol	NULL
on	NULL
ice	NULL
for	NULL
45	NULL
min	NULL
before	NULL
DNase	NULL
I	NULL
digestion	NULL
.	NULL

Gel	NULL
retardation	NULL
assays	NULL
.	NULL

A	NULL
10-fmol	NULL
portion	NULL
of	NULL
reverse	NULL
tran-scription-labeled	NULL
NRE	NULL
fragment	NULL
or	NULL
oligonucleotide	NULL
was	NULL
incubated	NULL
with	NULL
1.25	NULL
pg	NULL
of	NULL
Jurkat	NULL
T-cell	NULL
extract	NULL
on	NULL
ice	NULL
for	NULL
45	NULL
min	NULL
in	NULL
20	NULL
mM	NULL
HEPES	NULL
(	NULL
pH	NULL
7.9	NULL
)	NULL
-1	NULL
mM	NULL
MgCl	NULL
,	NULL
-50	NULL
mM	NULL
NaCl-4	NULL
%	NULL
Ficoll-5	NULL
ug	NULL
of	NULL
poly	NULL
(	NULL
dI	NULL
-	NULL
dC	NULL
)	NULL
with	NULL
competitor	NULL
as	NULL
indicated	NULL
and	NULL
then	NULL
separated	NULL
on	NULL
a	NULL
4	NULL
%	NULL
0.25	NULL
%	NULL
TBE-acryl-amide	NULL
gel	NULL
.	NULL

Methylation	NULL
interference	NULL
analysis	NULL
.	NULL

Labeled	NULL
NRE	NULL
fragment	NULL
PROTEIN-BINDING	NULL
SITES	NULL
IN	NULL
THE	NULL
NRE	NULL
OF	NULL
HIV-1	NULL
LTR	NULL
3235	NULL
E	NULL
aaï¬gggo	NULL
b	NULL
A	NULL
B	NULL
vam	NULL
_39-|	NULL
--	NULL
--	NULL
4	NULL
[	NULL
T	NULL
<	NULL
Z	NULL
|_320	NULL
we	NULL
CAAGGCTACTTCCCTGAT	NULL
TAGCAGAACTACACACCAGGGCCAGGGGTICAGATATCCACTGACCTTTGGATGG	NULL
GTTCCGATGAAGGGACTAMTCGTC	NULL
IGATGTGTGGTCPOGGTCCOCPGTCTATAGGTGACTGGAAACETAOC	NULL
I	NULL
*	NULL
Â®	NULL
Â®	NULL
I	NULL
B	NULL
Â«	NULL
0	NULL
%	NULL
I	NULL
Â«	NULL
b	NULL
@	NULL
:	NULL
zsass	NULL
s	NULL
u	NULL
wa	NULL
#	NULL
4	NULL
f	NULL
-	NULL
#	NULL
4	NULL
231A	NULL
i	NULL
L	NULL
io	NULL
it	NULL
;	NULL
We	NULL
``	NULL
*	NULL
%	NULL
--	NULL
%	NULL
%	NULL
go	NULL
-4|*	NULL
Â«	NULL
s	NULL
_	NULL
T	NULL
m	NULL
a	NULL
as	NULL
wo	NULL
th	NULL
â	NULL
am	NULL
aun	NULL
onn	NULL
ws	NULL
cnn	NULL
~A04424	NULL
%	NULL
.	NULL

FIG	NULL
.	NULL

1	NULL
.	NULL

DNase	NULL
I	NULL
footprinting	NULL
of	NULL
the	NULL
HIV-1	NULL
LTR	NULL
NRE	NULL
.	NULL

(	NULL
a	NULL
)	NULL
Lane	NULL
A	NULL
,	NULL
no	NULL
protein	NULL
;	NULL
lanes	NULL
B	NULL
through	NULL
E	NULL
,	NULL
labeled	NULL
NRE	NULL
fragment	NULL
incubated	NULL
with	NULL
Jurkat	NULL
T-cell	NULL
nuclear	NULL
extract	NULL
.	NULL

Lane	NULL
B	NULL
,	NULL
no	NULL
competitor	NULL
oligonucleotide	NULL
;	NULL
lane	NULL
C	NULL
,	NULL
site	NULL
A	NULL
oligonucleotide	NULL
;	NULL
lane	NULL
D	NULL
,	NULL
site	NULL
B	NULL
oligonucleotide	NULL
;	NULL
lane	NULL
E	NULL
,	NULL
sites	NULL
A	NULL
and	NULL
B	NULL
oligonucleotides	NULL
as	NULL
competitors	NULL
.	NULL

A	NULL
Maxam	NULL
and	NULL
Gilbert	NULL
G	NULL
reaction	NULL
(	NULL
12	NULL
)	NULL
of	NULL
the	NULL
NRE	NULL
fragment	NULL
used	NULL
as	NULL
a	NULL
marker	NULL
is	NULL
labeled	NULL
G.	NULL
(	NULL
b	NULL
)	NULL
Extent	NULL
of	NULL
the	NULL
DNase	NULL
I	NULL
footprint	NULL
on	NULL
each	NULL
strand	NULL
is	NULL
shown	NULL
.	NULL

The	NULL
patterns	NULL
of	NULL
methylation	NULL
interference	NULL
of	NULL
the	NULL
lower-mobility	NULL
complex	NULL
of	NULL
Fig	NULL
.	NULL

2	NULL
over	NULL
site	NULL
A	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
and	NULL
the	NULL
higher-mobility	NULL
complex	NULL
of	NULL
Fig	NULL
.	NULL

2	NULL
over	NULL
site	NULL
B	NULL
(	NULL
from	NULL
Fig	NULL
.	NULL

5	NULL
)	NULL
are	NULL
also	NULL
depicted	NULL
.	NULL

was	NULL
methylated	NULL
by	NULL
using	NULL
dimethyl	NULL
sulfate	NULL
such	NULL
that	NULL
,	NULL
on	NULL
average	NULL
,	NULL
one	NULL
G	NULL
residue	NULL
per	NULL
molecule	NULL
was	NULL
modified	NULL
and	NULL
then	NULL
was	NULL
run	NULL
in	NULL
a	NULL
DNA	NULL
mobility	NULL
shift	NULL
assay	NULL
scaled	NULL
up	NULL
10-fold	NULL
and	NULL
including	NULL
6	NULL
ug	NULL
of	NULL
pBR322	NULL
DNA	NULL
.	NULL

The	NULL
band	NULL
eliminated	NULL
by	NULL
competition	NULL
with	NULL
the	NULL
site	NULL
B	NULL
oligonucleotide	NULL
was	NULL
recovered	NULL
from	NULL
the	NULL
gel	NULL
and	NULL
the	NULL
DNA	NULL
was	NULL
purified	NULL
,	NULL
cleaved	NULL
by	NULL
using	NULL
piperidine	NULL
(	NULL
12	NULL
)	NULL
,	NULL
and	NULL
analyzed	NULL
on	NULL
a	NULL
sequencing	NULL
gel	NULL
.	NULL

CAT	NULL
assays	NULL
.	NULL

Reporter	NULL
plasmids	NULL
were	NULL
LTR-CAT	NULL
(	NULL
13	NULL
)	NULL
and	NULL
BMS	NULL
LTR-CAT	NULL
containing	NULL
the	NULL
7-base-pair	NULL
BMS	NULL
mutation	NULL
.	NULL

To	NULL
construct	NULL
BMS	NULL
LTR-CAT	NULL
,	NULL
a	NULL
42-base-pair	NULL
oligonucleotide	NULL
homologous	NULL
to	NULL
the	NULL
HIV-1	NULL
LTR	NULL
but	NULL
containing	NULL
a	NULL
central	NULL
7-base-pair	NULL
BMS	NULL
mutation	NULL
(	NULL
see	NULL
Fig	NULL
.	NULL

4a	NULL
)	NULL
was	NULL
used	NULL
in	NULL
site-directed	NULL
mutagenesis	NULL
of	NULL
a	NULL
557-base-pair	NULL
Kprnl-to-Sacl	NULL
fragment	NULL
of	NULL
HIV-HXB2	NULL
subcloned	NULL
in	NULL
M13	NULL
.	NULL

This	NULL
fragment	NULL
was	NULL
sequenced	NULL
and	NULL
then	NULL
substituted	NULL
in	NULL
LTR-CAT	NULL
.	NULL

Plasmids	NULL
were	NULL
quantitated	NULL
first	NULL
by	NULL
measurement	NULL
of	NULL
optical	NULL
density	NULL
at	NULL
280	NULL
nm	NULL
(	NULL
OD	NULL
;	NULL
s	NULL
,	NULL
)	NULL
and	NULL
then	NULL
on	NULL
an	NULL
ethidium	NULL
bromide-stained	NULL
agarose	NULL
gel	NULL
.	NULL

A	NULL
total	NULL
of	NULL
2	NULL
x	NULL
10	NULL
``	NULL
Jurkat-TAT	NULL
cells	NULL
were	NULL
transfected	NULL
by	NULL
incubation	NULL
with	NULL
plasmid	NULL
and	NULL
300	NULL
g	NULL
of	NULL
DEAE-dextran	NULL
per	NULL
ml	NULL
for	NULL
1	NULL
h.	NULL
After	NULL
48	NULL
h	NULL
,	NULL
chloramphenicol	NULL
acetyltransferase	NULL
(	NULL
CAT	NULL
)	NULL
enzyme	NULL
activity	NULL
was	NULL
measured	NULL
for	NULL
1	NULL
h.	NULL
Similar	NULL
results	NULL
of	NULL
duplicate	NULL
transfections	NULL
were	NULL
obtained	NULL
with	NULL
three	NULL
independent	NULL
plasmid	NULL
preparations	NULL
of	NULL
LTR-CAT	NULL
and	NULL
BMS	NULL
LTR-CAT	NULL
(	NULL
see	NULL
Fig	NULL
.	NULL

7	NULL
)	NULL
.	NULL

RESULTS	NULL
To	NULL
characterize	NULL
major	NULL
host	NULL
cell	NULL
proteins	NULL
interacting	NULL
with	NULL
the	NULL
upstream	NULL
NRE	NULL
of	NULL
the	NULL
HIV-1	NULL
LTR	NULL
,	NULL
we	NULL
carried	NULL
out	NULL
DNase	NULL
I	NULL
footprint	NULL
analysis	NULL
by	NULL
using	NULL
a	NULL
fragment	NULL
containing	NULL
bases	NULL
-456	NULL
to	NULL
-300	NULL
from	NULL
the	NULL
HXBH2	NULL
LTR	NULL
and	NULL
nuclear	NULL
extract	NULL
from	NULL
Jurkat	NULL
T	NULL
cells	NULL
,	NULL
which	NULL
are	NULL
permissive	NULL
for	NULL
HIV-1	NULL
infec-tion	NULL
.	NULL

This	NULL
fragment	NULL
was	NULL
selected	NULL
to	NULL
contain	NULL
the	NULL
NRE	NULL
as	NULL
defined	NULL
in	NULL
both	NULL
resting	NULL
and	NULL
activated	NULL
T	NULL
cells	NULL
(	NULL
19	NULL
)	NULL
but	NULL
to	NULL
lack	NULL
A	NULL
B	NULL
C	NULL
D	NULL
E	NULL
F	NULL
80	NULL
088	NULL
w	NULL
u	NULL
%	NULL
FIG	NULL
.	NULL

2	NULL
.	NULL

DNA	NULL
mobility	NULL
shift	NULL
assay	NULL
of	NULL
the	NULL
NRE	NULL
fragment	NULL
using	NULL
Jurkat	NULL
T-cell	NULL
nuclear	NULL
extract	NULL
.	NULL

Lane	NULL
A	NULL
,	NULL
no	NULL
competitor	NULL
;	NULL
lane	NULL
B	NULL
,	NULL
site	NULL
A	NULL
oligonucleotide	NULL
;	NULL
lane	NULL
C	NULL
,	NULL
site	NULL
B	NULL
oligonucleotide	NULL
;	NULL
lane	NULL
D	NULL
,	NULL
API	NULL
oligo-	NULL
nucleotide	NULL
;	NULL
lane	NULL
E	NULL
,	NULL
octamer	NULL
oligonucleotide	NULL
;	NULL
lane	NULL
F	NULL
,	NULL
pBR322	NULL
(	NULL
all	NULL
added	NULL
in	NULL
100-fold	NULL
molar	NULL
excess	NULL
)	NULL
.	NULL

3236	NULL
ORCHARD	NULL
ET	NULL
AL	NULL
.	NULL

a	NULL
A	NULL
BC	NULL
D	NULL
E	NULL
F	NULL
G	NULL
H	NULL
pA	NULL
BC	NULL
D	NULL
E	NULL
-	NULL
nome	NULL
ome	NULL
oms	NULL
M00	NULL
ut	NULL
itt	NULL
_	NULL
w	NULL
a	NULL
gf	NULL
'FIG	NULL
.	NULL

3	NULL
.	NULL

Further	NULL
characterization	NULL
of	NULL
site	NULL
B	NULL
.	NULL

(	NULL
a	NULL
)	NULL
DNA	NULL
mobility	NULL
shift	NULL
assay	NULL
with	NULL
labeled	NULL
site	NULL
B	NULL
oligonucleotide	NULL
and	NULL
Jurkat	NULL
T-cell	NULL
extract	NULL
.	NULL

Lanes	NULL
A	NULL
and	NULL
B	NULL
,	NULL
No	NULL
competitor	NULL
;	NULL
lane	NULL
C	NULL
,	NULL
site	NULL
B	NULL
oligonucleotide	NULL
;	NULL
lane	NULL
D	NULL
,	NULL
thyroid	NULL
hormone	NULL
response	NULL
element	NULL
;	NULL
lane	NULL
E	NULL
,	NULL
site	NULL
A	NULL
;	NULL
lane	NULL
F	NULL
,	NULL
simian	NULL
virus	NULL
40	NULL
enhancer	NULL
API	NULL
site	NULL
;	NULL
lane	NULL
G	NULL
,	NULL
simian	NULL
virus	NULL
40	NULL
enhancer	NULL
AP2	NULL
site	NULL
;	NULL
lane	NULL
H	NULL
,	NULL
pBR322	NULL
competition	NULL
at	NULL
100-fold	NULL
excess	NULL
.	NULL

All	NULL
extracts	NULL
were	NULL
from	NULL
activated	NULL
Jurkat	NULL
cells	NULL
except	NULL
track	NULL
A	NULL
(	NULL
nonactivated	NULL
Jurkat	NULL
cell	NULL
extract	NULL
)	NULL
.	NULL

(	NULL
b	NULL
)	NULL
Activated	NULL
Jurkat	NULL
T-cell	NULL
extract	NULL
was	NULL
incubated	NULL
for	NULL
30	NULL
min	NULL
on	NULL
ice	NULL
with	NULL
0.8	NULL
%	NULL
deoxycholate	NULL
and	NULL
0.5	NULL
%	NULL
Brij	NULL
(	NULL
lanes	NULL
B	NULL
through	NULL
D	NULL
)	NULL
before	NULL
a	NULL
DNA	NULL
mobility	NULL
shift	NULL
assay	NULL
with	NULL
no	NULL
competitor	NULL
(	NULL
lanes	NULL
A	NULL
and	NULL
B	NULL
)	NULL
,	NULL
or	NULL
100-fold	NULL
excess	NULL
of	NULL
site	NULL
B	NULL
oligonucleotide	NULL
(	NULL
lane	NULL
C	NULL
)	NULL
,	NULL
API	NULL
oligonucleotide	NULL
(	NULL
lane	NULL
D	NULL
)	NULL
,	NULL
or	NULL
octamer	NULL
oligonucleotide	NULL
(	NULL
lane	NULL
E	NULL
)	NULL
.	NULL

the	NULL
binding	NULL
site	NULL
for	NULL
the	NULL
potential	NULL
positive	NULL
regulatory	NULL
factor	NULL
NFAT1	NULL
present	NULL
in	NULL
such	NULL
cells	NULL
(	NULL
2	NULL
,	NULL
18	NULL
)	NULL
.	NULL

Figure	NULL
la	NULL
(	NULL
lane	NULL
B	NULL
)	NULL
shows	NULL
that	NULL
two	NULL
footprints	NULL
were	NULL
detectable	NULL
within	NULL
this	NULL
fragment	NULL
with	NULL
extract	NULL
from	NULL
activated	NULL
Jurkat	NULL
cells	NULL
.	NULL

These	NULL
are	NULL
located	NULL
at	NULL
-379	NULL
to	NULL
-361	NULL
(	NULL
site	NULL
A	NULL
)	NULL
and	NULL
-350	NULL
to	NULL
-327	NULL
(	NULL
site	NULL
B	NULL
)	NULL
and	NULL
are	NULL
represented	NULL
diagrammatically	NULL
in	NULL
Fig	NULL
.	NULL

1b	NULL
on	NULL
both	NULL
strands	NULL
(	NULL
data	NULL
for	NULL
the	NULL
bottom	NULL
strand	NULL
is	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

Each	NULL
of	NULL
these	NULL
footprints	NULL
was	NULL
eliminated	NULL
specifically	NULL
when	NULL
a	NULL
100-fold	NULL
excess	NULL
of	NULL
30-base-pair	NULL
oligonucleotides	NULL
spanning	NULL
the	NULL
appropriate	NULL
binding	NULL
site	NULL
was	NULL
included	NULL
in	NULL
the	NULL
assay	NULL
(	NULL
Fig	NULL
.	NULL

la	NULL
,	NULL
lanes	NULL
C	NULL
and	NULL
D	NULL
)	NULL
,	NULL
while	NULL
competition	NULL
with	NULL
both	NULL
sites	NULL
(	NULL
lane	NULL
E	NULL
)	NULL
resulted	NULL
in	NULL
a	NULL
DNase	NULL
I	NULL
cutting	NULL
pattern	NULL
indistinguishable	NULL
from	NULL
that	NULL
in	NULL
the	NULL
absence	NULL
of	NULL
nuclear	NULL
extract	NULL
.	NULL

Unrelated	NULL
oligonucle-	NULL
J.	NULL
ViroL	NULL
.	NULL

otides	NULL
had	NULL
no	NULL
effect	NULL
on	NULL
the	NULL
footprint	NULL
at	NULL
either	NULL
site	NULL
,	NULL
and	NULL
a	NULL
similar	NULL
footprint	NULL
was	NULL
observed	NULL
when	NULL
extract	NULL
from	NULL
nonactivated	NULL
Jurkat	NULL
cells	NULL
was	NULL
used	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

Although	NULL
the	NULL
footprint	NULL
over	NULL
each	NULL
of	NULL
these	NULL
sites	NULL
was	NULL
not	NULL
eliminated	NULL
by	NULL
competition	NULL
with	NULL
the	NULL
oligonucleotide	NULL
from	NULL
the	NULL
other	NULL
site	NULL
,	NULL
it	NULL
is	NULL
noteworthy	NULL
that	NULL
a	NULL
DNase	NULL
I-hypersensitive	NULL
site	NULL
at	NULL
the	NULL
border	NULL
of	NULL
site	NULL
B	NULL
(	NULL
arrowhead	NULL
in	NULL
Fig	NULL
.	NULL

la	NULL
,	NULL
lane	NULL
D	NULL
)	NULL
was	NULL
enhanced	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
the	NULL
site	NULL
A	NULL
footprint	NULL
when	NULL
the	NULL
site	NULL
B	NULL
footprint	NULL
had	NULL
been	NULL
specifically	NULL
eliminated	NULL
.	NULL

In	NULL
addition	NULL
,	NULL
there	NULL
was	NULL
a	NULL
much	NULL
enhanced	NULL
site	NULL
B	NULL
footprint	NULL
(	NULL
lane	NULL
C	NULL
)	NULL
and	NULL
associated	NULL
hypersensitivity	NULL
(	NULL
arrow	NULL
in	NULL
lane	NULL
C	NULL
)	NULL
when	NULL
site	NULL
A	NULL
was	NULL
eliminated	NULL
.	NULL

These	NULL
data	NULL
suggest	NULL
some	NULL
potential	NULL
interaction	NULL
between	NULL
the	NULL
two	NULL
sites	NULL
.	NULL

In	NULL
a	NULL
DNA	NULL
mobility	NULL
shift	NULL
assay	NULL
using	NULL
the	NULL
same	NULL
NRE	NULL
fragment	NULL
,	NULL
two	NULL
low-mobility	NULL
bands	NULL
were	NULL
observed	NULL
(	NULL
Fig	NULL
.	NULL

2	NULL
,	NULL
lane	NULL
A	NULL
)	NULL
.	NULL

As	NULL
expected	NULL
,	NULL
one	NULL
of	NULL
these	NULL
bands	NULL
(	NULL
that	NULL
with	NULL
the	NULL
lower	NULL
mobility	NULL
)	NULL
was	NULL
specifically	NULL
eliminated	NULL
by	NULL
competition	NULL
by	NULL
the	NULL
site	NULL
A	NULL
oligonucleotide	NULL
(	NULL
lane	NULL
B	NULL
)	NULL
,	NULL
while	NULL
the	NULL
other	NULL
was	NULL
similarly	NULL
eliminated	NULL
by	NULL
competition	NULL
with	NULL
a	NULL
site	NULL
B	NULL
oligonucleotide	NULL
(	NULL
lane	NULL
C	NULL
)	NULL
.	NULL

This	NULL
is	NULL
in	NULL
agreement	NULL
with	NULL
the	NULL
methylation	NULL
interference	NULL
pattern	NULL
obtained	NULL
over	NULL
site	NULL
B	NULL
with	NULL
the	NULL
higher-mobility	NULL
complex	NULL
(	NULL
Fig	NULL
.	NULL

1b	NULL
)	NULL
and	NULL
that	NULL
obtained	NULL
over	NULL
site	NULL
A	NULL
with	NULL
the	NULL
lower-mobility	NULL
complex	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

Hence	NULL
,	NULL
these	NULL
two	NULL
sites	NULL
represent	NULL
the	NULL
major	NULL
binding	NULL
sites	NULL
for	NULL
T-cell	NULL
factors	NULL
within	NULL
the	NULL
NRE	NULL
.	NULL

Minor	NULL
bands	NULL
which	NULL
are	NULL
potential	NULL
degradation	NULL
products	NULL
were	NULL
also	NULL
competed	NULL
by	NULL
site	NULL
B	NULL
;	NULL
neither	NULL
band	NULL
was	NULL
eliminated	NULL
by	NULL
competition	NULL
with	NULL
an	NULL
unrelated	NULL
sequence	NULL
(	NULL
lane	NULL
F	NULL
)	NULL
.	NULL

Inspection	NULL
of	NULL
the	NULL
sequence	NULL
of	NULL
site	NULL
A	NULL
(	NULL
Fig	NULL
.	NULL

1b	NULL
)	NULL
revealed	NULL
a	NULL
homology	NULL
with	NULL
the	NULL
octamer	NULL
element	NULL
,	NULL
which	NULL
binds	NULL
the	NULL
ubiquitous	NULL
transcription	NULL
factor	NULL
OTF-1	NULL
;	NULL
however	NULL
,	NULL
neither	NULL
complex	NULL
is	NULL
competed	NULL
by	NULL
an	NULL
oligonucleotide	NULL
containing	NULL
a	NULL
consensus	NULL
octamer	NULL
sequence	NULL
(	NULL
lane	NULL
E	NULL
)	NULL
.	NULL

An	NULL
oligonucleotide	NULL
related	NULL
to	NULL
the	NULL
site	NULL
B	NULL
region	NULL
,	NULL
but	NULL
with	NULL
multiple	NULL
sequence	NULL
changes	NULL
,	NULL
has	NULL
been	NULL
reported	NULL
to	NULL
bind	NULL
the	NULL
cellular	NULL
transcription	NULL
factor	NULL
API	NULL
(	NULL
4	NULL
)	NULL
,	NULL
but	NULL
an	NULL
oligonucleotide	NULL
containing	NULL
an	NULL
API-binding	NULL
site	NULL
failed	NULL
to	NULL
compete	NULL
for	NULL
either	NULL
complex	NULL
(	NULL
lane	NULL
D	NULL
)	NULL
.	NULL

In	NULL
view	NULL
of	NULL
the	NULL
strong	NULL
footprint	NULL
and	NULL
mobility	NULL
shift	NULL
given	NULL
by	NULL
site	NULL
B	NULL
,	NULL
we	NULL
decided	NULL
to	NULL
initially	NULL
characterize	NULL
the	NULL
protein	NULL
binding	NULL
to	NULL
site	NULL
B	NULL
.	NULL

To	NULL
do	NULL
this	NULL
,	NULL
we	NULL
performed	NULL
DNA	NULL
mobility	NULL
shift	NULL
analyses	NULL
with	NULL
a	NULL
site	NULL
B	NULL
oligonucleotide	NULL
.	NULL

This	NULL
revealed	NULL
a	NULL
single	NULL
major	NULL
DNA-protein	NULL
complex	NULL
with	NULL
a	NULL
nuclear	NULL
extract	NULL
from	NULL
activated	NULL
Jurkat	NULL
cells	NULL
(	NULL
Fig	NULL
.	NULL

3a	NULL
,	NULL
lane	NULL
B	NULL
)	NULL
which	NULL
was	NULL
eliminated	NULL
by	NULL
competition	NULL
with	NULL
an	NULL
unlabeled	NULL
site	NULL
B	NULL
oligonucleotide	NULL
(	NULL
Fig	NULL
.	NULL

3a	NULL
,	NULL
lane	NULL
C	NULL
)	NULL
but	NULL
not	NULL
with	NULL
site	NULL
A	NULL
oligonucleotide	NULL
(	NULL
Fig	NULL
.	NULL

3a	NULL
,	NULL
lane	NULL
E	NULL
)	NULL
or	NULL
plasmid	NULL
(	NULL
Fig	NULL
.	NULL

3a	NULL
,	NULL
lane	NULL
H	NULL
)	NULL
.	NULL

We	NULL
have	NULL
also	NULL
a	NULL
SITE	NULL
B	NULL
ERE	NULL
TRE	NULL
SITE	NULL
B	NULL
TCGACAGGGGTCAGATATCCACTGACCTTC	NULL
o	NULL
5s	NULL
Â«	NULL
0	NULL
Â¢Â°i\0	NULL
39	NULL
so	NULL
Â«	NULL
0Â°	NULL
aï¬p	NULL
g9	NULL
g0	NULL
{	NULL
301,00	NULL
a	NULL
>	NULL
Â«	NULL
-~	NULL
*	NULL
le	NULL
``	NULL
me	NULL
hater	NULL
:	NULL
saw	NULL
TRE	NULL
:	NULL
CGATCGTGCGGTCACGTCCCIGATCTTACCTTTCCA	NULL
ERE	NULL
:	NULL
CTAGAAAGTCAGGTCACAGTGACCTGATCAAT	NULL
GRE	NULL
CTAGAAAGTCAGAACACAGTGTTCTGATCAAT	NULL
BMS	NULL
TCGACACACTAGCGATATCCACTGACCTTC	NULL
BM3	NULL
:	NULL
TCGACAGGGGITCAGATATCCACGCTAGTGC	NULL
FIG	NULL
.	NULL

4	NULL
.	NULL

The	NULL
relationship	NULL
of	NULL
site	NULL
B	NULL
to	NULL
hormone	NULL
response	NULL
elements	NULL
.	NULL

(	NULL
a	NULL
)	NULL
Comparison	NULL
of	NULL
the	NULL
sequence	NULL
of	NULL
site	NULL
B	NULL
with	NULL
oligonucleotides	NULL
containing	NULL
a	NULL
TRElsequence	NULL
from	NULL
the	NULL
rat	NULL
growth	NULL
hormone	NULL
promoter	NULL
and	NULL
an	NULL
ERE	NULL
sequence	NULL
from	NULL
the	NULL
Xenopus	NULL
vitellogenin	NULL
A2	NULL
promoter	NULL
.	NULL

(	NULL
b	NULL
)	NULL
Gel	NULL
retardation	NULL
analysis	NULL
using	NULL
activated	NULL
Jurkat	NULL
cell	NULL
extract	NULL
,	NULL
labeled	NULL
site	NULL
B	NULL
oligonucleotide	NULL
,	NULL
and	NULL
the	NULL
excess	NULL
unlabeled	NULL
oligonucleotide	NULL
indicated	NULL
.	NULL

Vor	NULL
.	NULL

64	NULL
,	NULL
1990	NULL
detected	NULL
a	NULL
complex	NULL
with	NULL
a	NULL
similar	NULL
mobility	NULL
in	NULL
an	NULL
extract	NULL
from	NULL
nonactivated	NULL
Jurkat	NULL
cells	NULL
(	NULL
Fig	NULL
.	NULL

3a	NULL
,	NULL
lane	NULL
A	NULL
)	NULL
and	NULL
in	NULL
resting	NULL
and	NULL
stimulated	NULL
peripheral	NULL
blood	NULL
lymphocytes	NULL
and	NULL
HeLa	NULL
cells	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
,	NULL
suggesting	NULL
that	NULL
this	NULL
protein	NULL
is	NULL
ubiquitously	NULL
expressed	NULL
.	NULL

The	NULL
site	NULL
B	NULL
sequence	NULL
is	NULL
related	NULL
to	NULL
the	NULL
consensus	NULL
binding	NULL
sites	NULL
for	NULL
the	NULL
cellular	NULL
transcription	NULL
factors	NULL
AP1	NULL
and	NULL
AP2	NULL
.	NULL

However	NULL
,	NULL
the	NULL
binding	NULL
to	NULL
the	NULL
site	NULL
B	NULL
oligonucleotide	NULL
was	NULL
not	NULL
eliminated	NULL
by	NULL
competition	NULL
with	NULL
oligonucleotides	NULL
containing	NULL
the	NULL
simian	NULL
virus	NULL
40	NULL
enhancer	NULL
API	NULL
or	NULL
AP	NULL
?	NULL

sites	NULL
(	NULL
Fig	NULL
.	NULL

3a	NULL
,	NULL
tracks	NULL
F	NULL
and	NULL
G	NULL
)	NULL
;	NULL
therefore	NULL
,	NULL
these	NULL
are	NULL
not	NULL
the	NULL
predominant	NULL
proteins	NULL
binding	NULL
to	NULL
site	NULL
B	NULL
in	NULL
activated	NULL
T	NULL
cells	NULL
.	NULL

Indeed	NULL
,	NULL
an	NULL
antiserum	NULL
to	NULL
human	NULL
fos	NULL
protein	NULL
,	NULL
which	NULL
decreased	NULL
the	NULL
mobility	NULL
of	NULL
an	NULL
API	NULL
complex	NULL
,	NULL
had	NULL
no	NULL
effect	NULL
on	NULL
the	NULL
mobility	NULL
of	NULL
the	NULL
site	NULL
B	NULL
complex	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

An	NULL
intriguing	NULL
characteristic	NULL
of	NULL
the	NULL
site	NULL
B	NULL
complex	NULL
is	NULL
shown	NULL
in	NULL
Fig	NULL
.	NULL

3b	NULL
.	NULL

Treatment	NULL
of	NULL
protein	NULL
extracts	NULL
with	NULL
deoxycholate	NULL
and	NULL
Brij	NULL
,	NULL
a	NULL
combination	NULL
of	NULL
detergents	NULL
which	NULL
would	NULL
usually	NULL
disrupt	NULL
multiprotein	NULL
complexes	NULL
,	NULL
leading	NULL
to	NULL
increased	NULL
mobil-ity	NULL
,	NULL
surprisingly	NULL
resulted	NULL
in	NULL
a	NULL
marked	NULL
decrease	NULL
in	NULL
mobility	NULL
of	NULL
the	NULL
site	NULL
B	NULL
complex	NULL
(	NULL
Fig	NULL
.	NULL

3b	NULL
,	NULL
lane	NULL
B	NULL
)	NULL
.	NULL

This	NULL
lower-mobility	NULL
band	NULL
showed	NULL
the	NULL
same	NULL
specificity	NULL
of	NULL
competition	NULL
as	NULL
the	NULL
site	NULL
B	NULL
complex	NULL
(	NULL
Fig	NULL
.	NULL

3b	NULL
,	NULL
lanes	NULL
C	NULL
through	NULL
E	NULL
)	NULL
.	NULL

The	NULL
site	NULL
B-binding	NULL
protein	NULL
therefore	NULL
undergoes	NULL
a	NULL
characteristic	NULL
conformational	NULL
change	NULL
or	NULL
complex	NULL
formation	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
these	NULL
detergents	NULL
.	NULL

We	NULL
observed	NULL
in	NULL
our	NULL
initial	NULL
competition	NULL
experiments	NULL
that	NULL
site	NULL
B	NULL
binding	NULL
was	NULL
partially	NULL
eliminated	NULL
by	NULL
competition	NULL
with	NULL
a	NULL
100-fold	NULL
excess	NULL
of	NULL
synthetic	NULL
oligonucleotide	NULL
from	NULL
the	NULL
growth	NULL
hormone	NULL
promoter	NULL
(	NULL
Fig	NULL
.	NULL

3a	NULL
,	NULL
lane	NULL
D	NULL
)	NULL
.	NULL

Upon	NULL
inspection	NULL
of	NULL
the	NULL
site	NULL
B	NULL
sequence	NULL
(	NULL
Fig	NULL
.	NULL

4a	NULL
)	NULL
,	NULL
a	NULL
6-base-pair	NULL
palindrome	NULL
with	NULL
a	NULL
7-base-pair	NULL
spacing	NULL
can	NULL
be	NULL
identified	NULL
(	NULL
underlined	NULL
in	NULL
Fig	NULL
4a	NULL
)	NULL
,	NULL
which	NULL
is	NULL
homologous	NULL
to	NULL
a	NULL
palindromic	NULL
element	NULL
recognized	NULL
by	NULL
the	NULL
thyroid	NULL
hormone	NULL
receptor	NULL
(	NULL
TRE	NULL
)	NULL
within	NULL
the	NULL
growth	NULL
hormone	NULL
promoter	NULL
(	NULL
Fig	NULL
.	NULL

4a	NULL
)	NULL
.	NULL

In	NULL
the	NULL
growth	NULL
hormone	NULL
pro-moter	NULL
,	NULL
this	NULL
is	NULL
a	NULL
5-base-pair	NULL
palindrome	NULL
with	NULL
a	NULL
6-base-pair	NULL
spacing	NULL
.	NULL

Consideration	NULL
of	NULL
further	NULL
steroid	NULL
response	NULL
elements	NULL
led	NULL
to	NULL
the	NULL
observation	NULL
that	NULL
the	NULL
estrogen	NULL
receptor	NULL
recognition	NULL
site	NULL
(	NULL
ERE	NULL
)	NULL
also	NULL
has	NULL
considerable	NULL
homology	NULL
with	NULL
site	NULL
B	NULL
.	NULL

This	NULL
is	NULL
a	NULL
5-base-pair	NULL
palindrome	NULL
with	NULL
a	NULL
3-base-pair	NULL
spacing	NULL
(	NULL
Fig	NULL
.	NULL

4a	NULL
)	NULL
.	NULL

We	NULL
therefore	NULL
measured	NULL
the	NULL
affinity	NULL
of	NULL
interaction	NULL
of	NULL
the	NULL
site	NULL
B-binding	NULL
protein	NULL
with	NULL
TRE-	NULL
or	NULL
ERE-containing	NULL
oligo-nucleotides	NULL
.	NULL

The	NULL
ERE	NULL
was	NULL
recognized	NULL
with	NULL
an	NULL
approximately	NULL
threefold-lower	NULL
affinity	NULL
than	NULL
site	NULL
B	NULL
itself	NULL
,	NULL
and	NULL
the	NULL
TRE	NULL
was	NULL
recognized	NULL
with	NULL
an	NULL
approximately	NULL
20-fold-lower	NULL
affinity	NULL
(	NULL
Fig	NULL
.	NULL

4b	NULL
)	NULL
.	NULL

A	NULL
glucocorticoid	NULL
response	NULL
element	NULL
,	NULL
which	NULL
has	NULL
a	NULL
much	NULL
lower	NULL
homology	NULL
to	NULL
site	NULL
B	NULL
,	NULL
failed	NULL
to	NULL
compete	NULL
for	NULL
site	NULL
B	NULL
binding	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

The	NULL
ability	NULL
of	NULL
both	NULL
the	NULL
TRE-	NULL
and	NULL
ERE-containing	NULL
oligonucleotides	NULL
to	NULL
compete	NULL
for	NULL
site	NULL
B	NULL
binding	NULL
suggested	NULL
that	NULL
the	NULL
homologous	NULL
palindromic	NULL
sequence	NULL
present	NULL
in	NULL
site	NULL
B	NULL
might	NULL
be	NULL
that	NULL
recognized	NULL
by	NULL
the	NULL
protein	NULL
.	NULL

To	NULL
investigate	NULL
this	NULL
,	NULL
methylation	NULL
interference	NULL
analysis	NULL
was	NULL
performed	NULL
on	NULL
the	NULL
site	NULL
B	NULL
complex	NULL
,	NULL
which	NULL
revealed	NULL
a	NULL
symmetrical	NULL
pattern	NULL
of	NULL
interference	NULL
(	NULL
Fig	NULL
.	NULL

1b	NULL
and	NULL
5	NULL
)	NULL
identical	NULL
to	NULL
that	NULL
observed	NULL
by	NULL
others	NULL
studying	NULL
binding	NULL
to	NULL
the	NULL
TRE	NULL
or	NULL
ERE	NULL
.	NULL

The	NULL
site	NULL
B	NULL
protein	NULL
may	NULL
therefore	NULL
be	NULL
related	NULL
to	NULL
the	NULL
steroid/thyroid	NULL
hormone	NULL
receptor	NULL
family	NULL
,	NULL
binding	NULL
with	NULL
maximal	NULL
affinity	NULL
to	NULL
a	NULL
palindromic	NULL
sequence	NULL
with	NULL
a	NULL
longer	NULL
spacer	NULL
element	NULL
.	NULL

To	NULL
confirm	NULL
that	NULL
the	NULL
palindromic	NULL
sequence	NULL
in	NULL
site	NULL
B	NULL
was	NULL
important	NULL
for	NULL
protein	NULL
binding	NULL
,	NULL
mutations	NULL
were	NULL
introduced	NULL
which	NULL
destroyed	NULL
either	NULL
the	NULL
5	NULL
'	NULL
or	NULL
3	NULL
'	NULL
half	NULL
of	NULL
the	NULL
palindrome	NULL
(	NULL
BMS	NULL
and	NULL
BM3	NULL
,	NULL
respectively	NULL
;	NULL
Fig	NULL
.	NULL

4a	NULL
)	NULL
.	NULL

The	NULL
BMS	NULL
oligonucleotide	NULL
failed	NULL
to	NULL
form	NULL
a	NULL
protein	NULL
complex	NULL
,	NULL
while	NULL
the	NULL
BM3	NULL
oligonucleotide	NULL
formed	NULL
only	NULL
a	NULL
very	NULL
weak	NULL
specific	NULL
protein	NULL
complex	NULL
,	NULL
of	NULL
slightly	NULL
lower	NULL
mobility	NULL
than	NULL
that	NULL
formed	NULL
with	NULL
the	NULL
unmutated	NULL
site	NULL
B	NULL
(	NULL
Fig	NULL
.	NULL

6a	NULL
)	NULL
.	NULL

These	NULL
mutations	NULL
also	NULL
reduced	NULL
the	NULL
PROTEIN-BINDING	NULL
SITES	NULL
IN	NULL
THE	NULL
NRE	NULL
OF	NULL
HIV-1	NULL
LTR	NULL
3237	NULL
A	NULL
B	NULL
c	NULL
b	NULL
=v	NULL
Bee	NULL
#	NULL
0	NULL
ume	NULL
&	NULL
a	NULL
#	NULL
ws	NULL
dak	NULL
<	NULL
|	NULL
*	NULL
y	NULL
``	NULL
WB	NULL
cme	NULL
3	NULL
i	NULL
a	NULL
*	NULL
as	NULL
ltt	NULL
uke	NULL
@	NULL
#	NULL
s	NULL
:	NULL
s	NULL
*C	NULL
o	NULL
Â«	NULL
*	NULL
``	NULL
>	NULL
wp	NULL
like	NULL
4	NULL
an	NULL
UB	NULL
ma	NULL
@	NULL
B	NULL
as	NULL
F	NULL
wan	NULL
.	NULL

â¬HD	NULL
ces	NULL
%	NULL
it	NULL
FIG	NULL
.	NULL

5	NULL
.	NULL

Methylation	NULL
interference	NULL
on	NULL
the	NULL
NRE	NULL
complex	NULL
eliminated	NULL
by	NULL
competition	NULL
with	NULL
site	NULL
B	NULL
(	NULL
Fig	NULL
.	NULL

2	NULL
)	NULL
.	NULL

Lanes	NULL
A	NULL
and	NULL
B	NULL
,	NULL
NRE	NULL
fragment	NULL
labeled	NULL
on	NULL
the	NULL
bottom	NULL
strand	NULL
;	NULL
lanes	NULL
C	NULL
and	NULL
D	NULL
,	NULL
NRE	NULL
fragment	NULL
labeled	NULL
on	NULL
the	NULL
top	NULL
strand	NULL
;	NULL
either	NULL
unbound	NULL
DNA	NULL
(	NULL
lanes	NULL
B	NULL
and	NULL
C	NULL
)	NULL
or	NULL
DNA	NULL
recovered	NULL
from	NULL
the	NULL
protein-DNA	NULL
complex	NULL
.	NULL

Arrows	NULL
indicate	NULL
reduction	NULL
in	NULL
intensity	NULL
of	NULL
a	NULL
band	NULL
associated	NULL
with	NULL
the	NULL
complex	NULL
.	NULL

Representation	NULL
of	NULL
the	NULL
methylation	NULL
interference	NULL
patterns	NULL
of	NULL
sites	NULL
A	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
and	NULL
B	NULL
are	NULL
compared	NULL
with	NULL
the	NULL
extent	NULL
of	NULL
the	NULL
footprints	NULL
in	NULL
Fig	NULL
.	NULL

1b	NULL
.	NULL

ability	NULL
of	NULL
unlabeled	NULL
oligonucleotides	NULL
to	NULL
compete	NULL
for	NULL
binding	NULL
of	NULL
the	NULL
T-cell	NULL
protein	NULL
to	NULL
site	NULL
B	NULL
,	NULL
in	NULL
comparison	NULL
to	NULL
unmutated	NULL
site	NULL
B	NULL
(	NULL
Fig	NULL
.	NULL

6b	NULL
,	NULL
BMS	NULL
and	NULL
BM3	NULL
lanes	NULL
)	NULL
.	NULL

It	NULL
is	NULL
noteworthy	NULL
that	NULL
mutation	NULL
of	NULL
the	NULL
5	NULL
'	NULL
half	NULL
of	NULL
the	NULL
palindrome	NULL
decreased	NULL
binding	NULL
affinity	NULL
much	NULL
more	NULL
severely	NULL
(	NULL
a	NULL
100-fold	NULL
decrease	NULL
in	NULL
affinity	NULL
compared	NULL
with	NULL
a	NULL
fourfold	NULL
decrease	NULL
in	NULL
affinity	NULL
)	NULL
,	NULL
suggesting	NULL
that	NULL
this	NULL
part	NULL
of	NULL
the	NULL
element	NULL
is	NULL
more	NULL
important	NULL
for	NULL
protein	NULL
complex	NULL
formation	NULL
.	NULL

Similar	NULL
hierarchical	NULL
binding	NULL
to	NULL
halves	NULL
of	NULL
a	NULL
palindrome	NULL
has	NULL
been	NULL
described	NULL
for	NULL
the	NULL
glucocorticoid	NULL
receptor	NULL
responsive	NULL
element	NULL
(	NULL
21	NULL
)	NULL
and	NULL
may	NULL
indicate	NULL
that	NULL
the	NULL
sequences	NULL
flanking	NULL
the	NULL
palindrome	NULL
are	NULL
important	NULL
in	NULL
the	NULL
binding	NULL
interaction	NULL
.	NULL

Identification	NULL
of	NULL
the	NULL
BMS	NULL
mutation	NULL
,	NULL
a	NULL
7-base-pair	NULL
change	NULL
which	NULL
abolished	NULL
protein	NULL
interaction	NULL
,	NULL
allowed	NULL
the	NULL
effect	NULL
of	NULL
the	NULL
protein/site	NULL
B	NULL
interaction	NULL
on	NULL
HIV-1	NULL
LTR	NULL
transcription	NULL
to	NULL
be	NULL
measured	NULL
.	NULL

The	NULL
BMS	NULL
mutation	NULL
was	NULL
introduced	NULL
into	NULL
the	NULL
plasmid	NULL
LTR-CAT	NULL
,	NULL
which	NULL
was	NULL
then	NULL
transfected	NULL
into	NULL
Jurkat	NULL
cells	NULL
expressing	NULL
HIV-1	NULL
TAT	NULL
protein	NULL
so	NULL
that	NULL
the	NULL
basal	NULL
level	NULL
of	NULL
LTR	NULL
expression	NULL
could	NULL
be	NULL
readily	NULL
detected	NULL
.	NULL

A	NULL
comparison	NULL
of	NULL
BMS	NULL
LTR-CAT	NULL
expression	NULL
with	NULL
that	NULL
of	NULL
the	NULL
wild-type	NULL
LTR	NULL
CAT	NULL
is	NULL
shown	NULL
in	NULL
Fig	NULL
.	NULL

7	NULL
;	NULL
an	NULL
approximately	NULL
twofold	NULL
increase	NULL
in	NULL
expression	NULL
from	NULL
the	NULL
BMS	NULL
LTR	NULL
was	NULL
seen	NULL
with	NULL
a	NULL
range	NULL
of	NULL
plasmid	NULL
concentrations	NULL
.	NULL

This	NULL
result	NULL
was	NULL
obtained	NULL
with	NULL
three	NULL
3238	NULL
ORCHARD	NULL
ET	NULL
AL	NULL
.	NULL

SITE	NULL
B	NULL
BM3	NULL
BMS	NULL
A	NULL
B	NULL
C	NULL
D	NULL
EF	NULL
G	NULL
H	NULL
I|	NULL
J|K	NULL
L	NULL
M	NULL
N	NULL
O	NULL
b	NULL
Â«	NULL
in	NULL
PROBE	NULL
a	NULL
0	NULL
>	NULL
@	NULL
a	NULL
0	NULL
BMS	NULL
0	NULL
0	NULL
o	NULL
o	NULL
6	NULL
.	NULL

%	NULL
W0	NULL
57Â°	NULL
Ns	NULL
Â«	NULL
0	NULL
W0	NULL
s	NULL
.o	NULL
W0	NULL
(	NULL
9Â°	NULL
\0Â°rÂ§	NULL
â	NULL
BM3	NULL
:	NULL
P060	NULL
FIG	NULL
.	NULL

6	NULL
.	NULL

Effect	NULL
of	NULL
mutations	NULL
in	NULL
the	NULL
site	NULL
B	NULL
palindrome	NULL
on	NULL
protein	NULL
binding	NULL
.	NULL

(	NULL
a	NULL
)	NULL
Mobility	NULL
shift	NULL
assays	NULL
using	NULL
labeled	NULL
site	NULL
B	NULL
,	NULL
BM3	NULL
,	NULL
or	NULL
BMS	NULL
oligonucleotides	NULL
as	NULL
indicated	NULL
above	NULL
lanes	NULL
and	NULL
no	NULL
competitor	NULL
(	NULL
lanes	NULL
A	NULL
,	NULL
F	NULL
,	NULL
and	NULL
K	NULL
)	NULL
,	NULL
unlabeled	NULL
site	NULL
B	NULL
oligonucleotide	NULL
(	NULL
lanes	NULL
B	NULL
,	NULL
G	NULL
,	NULL
and	NULL
L	NULL
)	NULL
,	NULL
BMS	NULL
oligonucleotide	NULL
(	NULL
lanes	NULL
C	NULL
,	NULL
H	NULL
,	NULL
and	NULL
M	NULL
)	NULL
,	NULL
BM3	NULL
oligonucleotide	NULL
(	NULL
lanes	NULL
D	NULL
,	NULL
I	NULL
,	NULL
and	NULL
N	NULL
)	NULL
,	NULL
or	NULL
API	NULL
oligonucleotide	NULL
(	NULL
lanes	NULL
E	NULL
,	NULL
J	NULL
,	NULL
and	NULL
O	NULL
)	NULL
at	NULL
100-fold	NULL
molar	NULL
excess	NULL
.	NULL

(	NULL
b	NULL
)	NULL
Labeled	NULL
site	NULL
B	NULL
oligonucleotide	NULL
with	NULL
the	NULL
fold	NULL
excess	NULL
of	NULL
the	NULL
unlabeled	NULL
competitor	NULL
oligonucleotide	NULL
indicated	NULL
above	NULL
the	NULL
lanes	NULL
.	NULL

independent	NULL
plasmid	NULL
preparations	NULL
of	NULL
both	NULL
BMS	NULL
LTR-CAT	NULL
and	NULL
LTR-CAT	NULL
in	NULL
the	NULL
monocytic	NULL
cell	NULL
line	NULL
U937	NULL
and	NULL
in	NULL
activated	NULL
Jurkat	NULL
cells	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

The	NULL
protein	NULL
inter	NULL
acting	NULL
with	NULL
site	NULL
B	NULL
therefore	NULL
acts	NULL
as	NULL
a	NULL
weak	NULL
repressor	NULL
of	NULL
the	NULL
LTR	NULL
.	NULL

DISCUSSION	NULL
In	NULL
this	NULL
report	NULL
,	NULL
we	NULL
have	NULL
identified	NULL
two	NULL
regions	NULL
of	NULL
the	NULL
HIV-1	NULL
LTR	NULL
NRE	NULL
which	NULL
lie	NULL
between	NULL
-323	NULL
and	NULL
-383	NULL
and	NULL
which	NULL
interact	NULL
with	NULL
previously	NULL
uncharacterized	NULL
proteins	NULL
present	NULL
in	NULL
human	NULL
T	NULL
cells	NULL
.	NULL

Both	NULL
of	NULL
the	NULL
elements	NULL
that	NULL
we	NULL
have	NULL
defined	NULL
are	NULL
conserved	NULL
in	NULL
all	NULL
sequenced	NULL
strains	NULL
of	NULL
HIV-1	NULL
;	NULL
part	NULL
of	NULL
this	NULL
conservation	NULL
can	NULL
be	NULL
ascribed	NULL
to	NULL
the	NULL
fact	NULL
that	NULL
these	NULL
elements	NULL
lie	NULL
within	NULL
the	NULL
coding	NULL
region	NULL
for	NULL
the	NULL
HIV	NULL
regulatory	NULL
protein	NULL
nef	NULL
.	NULL

However	NULL
,	NULL
base	NULL
3	NULL
conservation	NULL
in	NULL
nef	NULL
codons	NULL
suggests	NULL
that	NULL
they	NULL
are	NULL
also	NULL
conserved	NULL
as	NULL
LTR	NULL
elements	NULL
.	NULL

Mutation	NULL
of	NULL
the	NULL
binding	NULL
site	NULL
(	NULL
site	NULL
B	NULL
)	NULL
for	NULL
one	NULL
factor	NULL
resulted	NULL
in	NULL
a	NULL
two-	NULL
to	NULL
three-fold	NULL
increase	NULL
in	NULL
LTR	NULL
activity	NULL
,	NULL
identifying	NULL
this	NULL
protein	NULL
as	NULL
a	NULL
weak	NULL
repressor	NULL
of	NULL
HIV-1	NULL
LTR-driven	NULL
gene	NULL
expression	NULL
.	NULL

We	NULL
are	NULL
currently	NULL
extending	NULL
this	NULL
analysis	NULL
to	NULL
the	NULL
site	NULL
A	NULL
J.	NULL
ViroL	NULL
.	NULL

<	NULL
e	NULL
LJ	NULL
Â©	NULL
#	NULL
%	NULL
Â©	NULL
A	NULL
@	NULL
#	NULL
â¬	NULL
Â®	NULL
&	NULL
1285	NULL
.	NULL

2s	NULL
..	NULL
:	NULL
s	NULL
.	NULL

1	NULL
2	NULL
A25	NULL
256.	NULL
s	NULL
J	NULL
2	NULL
.	NULL

2	NULL
ham	NULL
[	NULL
C.	NULL
ith	NULL
...	NULL
acd	NULL
BMS	NULL
LTR-CAT	NULL
LTR-CAT	NULL
11	NULL
17	NULL
31	NULL
40	NULL
32	NULL
9	NULL
1C	NULL
11	NULL
16	NULL
17	NULL
FIG	NULL
.	NULL

7	NULL
.	NULL

Expression	NULL
of	NULL
HIV-1	NULL
LTR	NULL
CAT	NULL
with	NULL
a	NULL
mutated	NULL
site	NULL
B.	NULL
LTR	NULL
CAT	NULL
or	NULL
BMS	NULL
LTR	NULL
CAT	NULL
in	NULL
the	NULL
amounts	NULL
indicated	NULL
below	NULL
the	NULL
lanes	NULL
were	NULL
introduced	NULL
into	NULL
Jurkat	NULL
TAT	NULL
cells	NULL
by	NULL
DEAE-dextran-mediated	NULL
transfection	NULL
.	NULL

After	NULL
48	NULL
h	NULL
,	NULL
CAT	NULL
activity	NULL
was	NULL
measured	NULL
;	NULL
the	NULL
percent	NULL
conversion	NULL
values	NULL
(	NULL
bottom	NULL
)	NULL
were	NULL
calculated	NULL
by	NULL
counting	NULL
the	NULL
corresponding	NULL
areas	NULL
of	NULL
the	NULL
plate	NULL
and	NULL
are	NULL
the	NULL
means	NULL
of	NULL
duplicate	NULL
parallel	NULL
transfections	NULL
.	NULL

protein	NULL
,	NULL
which	NULL
footprint	NULL
analysis	NULL
suggests	NULL
interacts	NULL
with	NULL
the	NULL
site	NULL
B	NULL
protein	NULL
(	NULL
Fig	NULL
.	NULL

la	NULL
)	NULL
.	NULL

In	NULL
previous	NULL
studies	NULL
,	NULL
a	NULL
region	NULL
containing	NULL
site	NULL
B	NULL
has	NULL
been	NULL
reported	NULL
to	NULL
have	NULL
a	NULL
threefold	NULL
negative	NULL
effect	NULL
on	NULL
HIV-1	NULL
LTR-driven	NULL
gene	NULL
expression	NULL
(	NULL
19	NULL
)	NULL
,	NULL
and	NULL
it	NULL
is	NULL
probable	NULL
,	NULL
therefore	NULL
,	NULL
that	NULL
binding	NULL
to	NULL
site	NULL
B	NULL
contributes	NULL
to	NULL
this	NULL
effect	NULL
.	NULL

However	NULL
,	NULL
the	NULL
negative	NULL
regulatory	NULL
region	NULL
in	NULL
another	NULL
study	NULL
lies	NULL
downstream	NULL
of	NULL
-340	NULL
(	NULL
17	NULL
)	NULL
,	NULL
containing	NULL
only	NULL
part	NULL
of	NULL
site	NULL
B	NULL
,	NULL
and	NULL
the	NULL
negative	NULL
effect	NULL
in	NULL
this	NULL
case	NULL
must	NULL
therefore	NULL
involve	NULL
further	NULL
cellular	NULL
factors	NULL
binding	NULL
to	NULL
this	NULL
adjacent	NULL
region	NULL
.	NULL

In	NULL
the	NULL
intact	NULL
,	NULL
integrated	NULL
LTR	NULL
such	NULL
proteins	NULL
may	NULL
interact	NULL
with	NULL
the	NULL
site	NULL
B	NULL
binding	NULL
protein	NULL
in	NULL
a	NULL
manner	NULL
similar	NULL
to	NULL
that	NULL
of	NULL
the	NULL
site	NULL
A	NULL
protein	NULL
.	NULL

The	NULL
identification	NULL
of	NULL
a	NULL
putative	NULL
hormone	NULL
receptor	NULL
palindromic	NULL
element	NULL
with	NULL
a	NULL
novel	NULL
spacing	NULL
provides	NULL
several	NULL
potential	NULL
mechanisms	NULL
for	NULL
negative	NULL
regulation	NULL
at	NULL
site	NULL
B	NULL
.	NULL

Thus	NULL
,	NULL
although	NULL
the	NULL
palindrome	NULL
we	NULL
have	NULL
defined	NULL
bears	NULL
a	NULL
close	NULL
relationship	NULL
to	NULL
the	NULL
similar	NULL
elements	NULL
in	NULL
the	NULL
TRE	NULL
and	NULL
ERE	NULL
,	NULL
it	NULL
differs	NULL
from	NULL
these	NULL
in	NULL
the	NULL
spacing	NULL
between	NULL
the	NULL
two	NULL
halves	NULL
of	NULL
the	NULL
palindrome	NULL
(	NULL
Fig	NULL
.	NULL

4a	NULL
)	NULL
.	NULL

In	NULL
the	NULL
case	NULL
of	NULL
the	NULL
site	NULL
B	NULL
palindrome	NULL
,	NULL
this	NULL
spacing	NULL
is	NULL
7	NULL
base	NULL
pairs	NULL
,	NULL
whereas	NULL
TREs	NULL
possess	NULL
a	NULL
6-base-pair	NULL
spacing	NULL
or	NULL
are	NULL
contiguous	NULL
,	NULL
while	NULL
EREs	NULL
have	NULL
a	NULL
3-base-pair	NULL
spacing	NULL
.	NULL

Such	NULL
differences	NULL
are	NULL
of	NULL
particular	NULL
significance	NULL
in	NULL
that	NULL
previous	NULL
studies	NULL
have	NULL
shown	NULL
that	NULL
the	NULL
thyroid	NULL
hormone	NULL
receptor	NULL
can	NULL
repress	NULL
transcription	NULL
from	NULL
binding	NULL
sites	NULL
with	NULL
an	NULL
extended	NULL
spacing	NULL
(	NULL
6	NULL
)	NULL
.	NULL

Similarly	NULL
,	NULL
this	NULL
receptor	NULL
has	NULL
been	NULL
reported	NULL
to	NULL
repress	NULL
expression	NULL
via	NULL
a	NULL
retinoic	NULL
acid	NULL
receptor-binding	NULL
site	NULL
in	NULL
the	NULL
absence	NULL
of	NULL
ligand	NULL
(	NULL
7	NULL
)	NULL
.	NULL

Moreover	NULL
an	NULL
alternatively	NULL
spliced	NULL
form	NULL
of	NULL
the	NULL
thyroid	NULL
hormone	NULL
receptor	NULL
has	NULL
been	NULL
defined	NULL
which	NULL
lacks	NULL
the	NULL
ligand-binding	NULL
domain	NULL
and	NULL
dominantly	NULL
represses	NULL
gene	NULL
expression	NULL
(	NULL
9	NULL
)	NULL
.	NULL

It	NULL
is	NULL
possible	NULL
,	NULL
therefore	NULL
,	NULL
that	NULL
the	NULL
site	NULL
B-binding	NULL
protein	NULL
may	NULL
act	NULL
similarly	NULL
to	NULL
repress	NULL
HIV-1	NULL
gene	NULL
expression	NULL
,	NULL
either	NULL
because	NULL
it	NULL
is	NULL
not	NULL
a	NULL
ligand-binding	NULL
protein	NULL
or	NULL
because	NULL
its	NULL
specific	NULL
ligand	NULL
is	NULL
absent	NULL
in	NULL
our	NULL
experiments	NULL
.	NULL

The	NULL
sequence	NULL
specificity	NULL
of	NULL
the	NULL
site	NULL
B-binding	NULL
protein	NULL
and	NULL
its	NULL
pattern	NULL
of	NULL
expression	NULL
indicate	NULL
that	NULL
it	NULL
is	NULL
not	NULL
a	NULL
previously	NULL
characterized	NULL
protein	NULL
.	NULL

Analysis	NULL
of	NULL
the	NULL
precise	NULL
relationship	NULL
of	NULL
this	NULL
protein	NULL
to	NULL
the	NULL
steroid/thyroid	NULL
hormone	NULL
receptor	NULL
family	NULL
must	NULL
await	NULL
further	NULL
study	NULL
.	NULL

The	NULL
role	NULL
of	NULL
this	NULL
protein	NULL
in	NULL
the	NULL
regulation	NULL
of	NULL
HIV-1	NULL
gene	NULL
expression	NULL
,	NULL
and	NULL
potentially	NULL
in	NULL
the	NULL
regulation	NULL
of	NULL
specific	NULL
cellular	NULL
genes	NULL
,	NULL
suggests	NULL
that	NULL
such	NULL
a	NULL
study	NULL
would	NULL
be	NULL
of	NULL
interest	NULL
.	NULL

Vor	NULL
.	NULL

64	NULL
,	NULL
1990	NULL
PROTEIN-BINDING	NULL
SITES	NULL
IN	NULL
THE	NULL
NRE	NULL
OF	NULL
HIV-1	NULL
LTR	NULL
3239	NULL
ACKNOWLEDGMENTS	NULL
The	NULL
contributions	NULL
of	NULL
the	NULL
first	NULL
two	NULL
authors	NULL
to	NULL
this	NULL
study	NULL
were	NULL
equivalent	NULL
.	NULL

We	NULL
thank	NULL
Robin	NULL
Weiss	NULL
for	NULL
critical	NULL
reading	NULL
of	NULL
the	NULL
manuscript	NULL
,	NULL
Malcolm	NULL
Parker	NULL
for	NULL
ERE/GRE	NULL
oligonucleotides	NULL
,	NULL
Jonathan	NULL
Karn	NULL
for	NULL
the	NULL
TAT	NULL
retroviral	NULL
vector	NULL
,	NULL
and	NULL
Lawrence	NULL
Pearl	NULL
for	NULL
sequence	NULL
analysis	NULL
.	NULL

This	NULL
work	NULL
was	NULL
supported	NULL
by	NULL
the	NULL
AIDS	NULL
Directed	NULL
Programme	NULL
of	NULL
the	NULL
Medical	NULL
Research	NULL
Council	NULL
and	NULL
the	NULL
Cancer	NULL
Research	NULL
Campaign	NULL
.	NULL

LITERATURE	NULL
CITED	NULL
1	NULL
.	NULL

Beato	NULL
,	NULL
M.	NULL
1989	NULL
.	NULL

Gene	NULL
regulation	NULL
by	NULL
steroid	NULL
hormones	NULL
.	NULL

Cell	NULL
56:335-344	NULL
.	NULL

2	NULL
.	NULL

Bohnlein	NULL
,	NULL
E.	NULL
,	NULL
J.	NULL
W.	NULL
Lowenthal	NULL
,	NULL
M.	NULL
Siekevitz	NULL
,	NULL
D.	NULL
W.	NULL
Ballard	NULL
,	NULL
B.	NULL
R.	NULL
Franza	NULL
,	NULL
and	NULL
W.	NULL
C.	NULL
Greene	NULL
.	NULL

1988	NULL
.	NULL

The	NULL
same	NULL
inducible	NULL
nuclear	NULL
protein	NULL
regulates	NULL
mitogen	NULL
activation	NULL
of	NULL
both	NULL
the	NULL
interleukin-2	NULL
receptor-alpha	NULL
gene	NULL
and	NULL
type	NULL
1	NULL
HIV	NULL
.	NULL

Cell	NULL
53:827-836	NULL
.	NULL

2	NULL
.	NULL

Dignam	NULL
,	NULL
J.	NULL
D.	NULL
,	NULL
R.	NULL
M.	NULL
Lebowitz	NULL
,	NULL
and	NULL
R.	NULL
G.	NULL
Roeder	NULL
.	NULL

1983	NULL
.	NULL

Accurate	NULL
transcription	NULL
initiation	NULL
by	NULL
RNA	NULL
polymerase	NULL
II	NULL
in	NULL
a	NULL
soluble	NULL
extract	NULL
from	NULL
isolated	NULL
mammalian	NULL
nuclei	NULL
.	NULL

Nucleic	NULL
Acids	NULL
Res	NULL
.	NULL

11:1475-1489	NULL
.	NULL

4	NULL
.	NULL

Franza	NULL
,	NULL
B.	NULL
R.	NULL
,	NULL
F.	NULL
J.	NULL
Rauscher	NULL
,	NULL
S.	NULL
F.	NULL
Josephs	NULL
,	NULL
and	NULL
T.	NULL
Curran	NULL
.	NULL

1988	NULL
.	NULL

The	NULL
Fos	NULL
complex	NULL
and	NULL
Fos-related	NULL
antigens	NULL
recognize	NULL
sequence	NULL
elements	NULL
that	NULL
contain	NULL
AP-1	NULL
binding	NULL
sites	NULL
.	NULL

Science	NULL
239:1150-1153	NULL
.	NULL

5	NULL
.	NULL

Garcia	NULL
,	NULL
J	NULL
.	NULL

A.	NULL
,	NULL
F.	NULL
K.	NULL
Wu	NULL
,	NULL
R.	NULL
Mitsuyasu	NULL
,	NULL
and	NULL
R.	NULL
B.	NULL
Gaynor	NULL
.	NULL

1987	NULL
.	NULL

Interactions	NULL
of	NULL
cellular	NULL
proteins	NULL
involved	NULL
in	NULL
the	NULL
transcriptional	NULL
regulation	NULL
of	NULL
the	NULL
human	NULL
immunodeficiency	NULL
virus	NULL
.	NULL

EMBO	NULL
J	NULL
.	NULL

6:3761-3770	NULL
.	NULL

6	NULL
.	NULL

Glass	NULL
,	NULL
C.	NULL
K.	NULL
,	NULL
J.	NULL
M.	NULL
Holloway	NULL
,	NULL
O.	NULL
V.	NULL
Devary	NULL
,	NULL
and	NULL
M.	NULL
G.	NULL
Rosenfeld	NULL
.	NULL

1988	NULL
.	NULL

The	NULL
thyroid	NULL
hormone	NULL
receptor	NULL
binds	NULL
with	NULL
opposite	NULL
transcriptional	NULL
effects	NULL
to	NULL
a	NULL
common	NULL
sequence	NULL
motif	NULL
in	NULL
thyroid	NULL
hormone	NULL
and	NULL
estrogen	NULL
response	NULL
elements	NULL
.	NULL

Cell	NULL
54	NULL
:	NULL
313-323	NULL
.	NULL

7	NULL
.	NULL

Graupner	NULL
,	NULL
G.	NULL
,	NULL
K.	NULL
N.	NULL
Wills	NULL
,	NULL
M.	NULL
Tzukerman	NULL
,	NULL
X.	NULL
Zhang	NULL
,	NULL
and	NULL
M.	NULL
Pfahl	NULL
.	NULL

1989	NULL
.	NULL

Dual	NULL
regulatory	NULL
role	NULL
for	NULL
thyroid-hormone	NULL
receptors	NULL
allows	NULL
control	NULL
of	NULL
retinoic	NULL
acid	NULL
receptor	NULL
activity	NULL
.	NULL

Nature	NULL
(	NULL
London	NULL
)	NULL
340:653-656	NULL
.	NULL

8	NULL
.	NULL

Griffin	NULL
,	NULL
G.	NULL
E.	NULL
,	NULL
K.	NULL
Leung	NULL
,	NULL
T.	NULL
M.	NULL
Folks	NULL
,	NULL
S.	NULL
Kundel	NULL
,	NULL
and	NULL
G.	NULL
J.	NULL
Nabel	NULL
.	NULL

1989	NULL
.	NULL

Activation	NULL
of	NULL
HIV	NULL
gene	NULL
expression	NULL
during	NULL
mono-cyte	NULL
differentiation	NULL
by	NULL
induction	NULL
of	NULL
NF-xB	NULL
.	NULL

Nature	NULL
(	NULL
London	NULL
)	NULL
339:70-73	NULL
.	NULL

9	NULL
.	NULL

Koenig	NULL
,	NULL
R.	NULL
J.	NULL
,	NULL
M.	NULL
A.	NULL
Lazar	NULL
,	NULL
R.	NULL
A.	NULL
Hodin	NULL
,	NULL
G.	NULL
A.	NULL
Brent	NULL
,	NULL
P.	NULL
R.	NULL
Larsen	NULL
,	NULL
W.	NULL
W.	NULL
Chin	NULL
,	NULL
and	NULL
D.	NULL
D.	NULL
Moore	NULL
.	NULL

1989	NULL
.	NULL

Inhibition	NULL
of	NULL
thyroid	NULL
hormone	NULL
action	NULL
by	NULL
a	NULL
non-hormone	NULL
binding	NULL
c-erbA	NULL
protein	NULL
generated	NULL
by	NULL
alternative	NULL
mRNA	NULL
splicing	NULL
.	NULL

Nature	NULL
(	NULL
London	NULL
)	NULL
337:659-661	NULL
.	NULL

10	NULL
.	NULL

Lowenthal	NULL
,	NULL
J.	NULL
W.	NULL
,	NULL
D.	NULL
W.	NULL
Ballard	NULL
,	NULL
E.	NULL
Bohnlein	NULL
,	NULL
and	NULL
W.	NULL
C.	NULL
11	NULL
.	NULL

12	NULL
.	NULL

13	NULL
.	NULL

14	NULL
.	NULL

15	NULL
.	NULL

16	NULL
.	NULL

17	NULL
.	NULL

18	NULL
.	NULL

19	NULL
.	NULL

20	NULL
.	NULL

21	NULL
.	NULL

Greene	NULL
.	NULL

1989	NULL
.	NULL

Tumor	NULL
necrosis	NULL
factor	NULL
a	NULL
induces	NULL
proteins	NULL
that	NULL
bind	NULL
specifically	NULL
to	NULL
kB-like	NULL
enhancer	NULL
elements	NULL
and	NULL
regulate	NULL
interleukin	NULL
2	NULL
receptor	NULL
Â«	NULL
-chain	NULL
gene	NULL
expression	NULL
in	NULL
primary	NULL
human	NULL
T-lymphocytes	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
86:2331-2335	NULL
.	NULL

Lu	NULL
,	NULL
Y.	NULL
,	NULL
M.	NULL
Stenzel	NULL
,	NULL
J.	NULL
G.	NULL
Sodroski	NULL
,	NULL
and	NULL
W.	NULL
A.	NULL
Haseltine	NULL
.	NULL

1989	NULL
.	NULL

Effects	NULL
of	NULL
long	NULL
terminal	NULL
repeat	NULL
mutations	NULL
on	NULL
human	NULL
immunodeficiency	NULL
virus	NULL
type	NULL
1	NULL
.	NULL

J.	NULL
Virol	NULL
.	NULL

63:4115-4119	NULL
.	NULL

Maxam	NULL
,	NULL
A.	NULL
M.	NULL
,	NULL
and	NULL
W.	NULL
Gilbert	NULL
.	NULL

1980	NULL
.	NULL

Sequencing	NULL
end-labeled	NULL
DNA	NULL
with	NULL
base-specific	NULL
chemical	NULL
cleavage	NULL
.	NULL

Methods	NULL
Enzymol	NULL
.	NULL

65:499-560	NULL
.	NULL

Nabel	NULL
,	NULL
G.	NULL
,	NULL
and	NULL
D.	NULL
Baltimore	NULL
.	NULL

1987	NULL
.	NULL

An	NULL
inducible	NULL
transcription	NULL
factor	NULL
activates	NULL
expression	NULL
of	NULL
human	NULL
immunodeficiency	NULL
virus	NULL
in	NULL
T	NULL
cells	NULL
.	NULL

Nature	NULL
(	NULL
London	NULL
)	NULL
326:711-713	NULL
.	NULL

Osborn	NULL
,	NULL
L.	NULL
,	NULL
S.	NULL
Kunkel	NULL
,	NULL
and	NULL
G.	NULL
J.	NULL
Nabel	NULL
.	NULL

1989	NULL
.	NULL

Tumor	NULL
necrosis	NULL
factor	NULL
and	NULL
interleukin	NULL
1	NULL
stimulate	NULL
the	NULL
human	NULL
immunodeficiency	NULL
virus	NULL
enhancer	NULL
by	NULL
activation	NULL
of	NULL
the	NULL
nuclear	NULL
factor	NULL
kB	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
86:2336-2340	NULL
.	NULL

Perkins	NULL
,	NULL
N.	NULL
D.	NULL
,	NULL
R.	NULL
H.	NULL
Nicolas	NULL
,	NULL
M.	NULL
A.	NULL
Plumb	NULL
,	NULL
and	NULL
G.	NULL
H.	NULL
Goodwin	NULL
.	NULL

1989	NULL
.	NULL

The	NULL
purification	NULL
of	NULL
an	NULL
erythroid	NULL
protein	NULL
which	NULL
binds	NULL
to	NULL
enhancer	NULL
and	NULL
promoter	NULL
elements	NULL
of	NULL
haemoglobin	NULL
genes	NULL
.	NULL

Nucleic	NULL
Acids	NULL
Res	NULL
.	NULL

17:1299-1314	NULL
.	NULL

Plumb	NULL
,	NULL
M.	NULL
A.	NULL
,	NULL
V.	NULL
V.	NULL
Lobanenkov	NULL
,	NULL
R.	NULL
H.	NULL
Nicolas	NULL
,	NULL
C.	NULL
A.	NULL
Wright	NULL
,	NULL
S.	NULL
Zavou	NULL
,	NULL
and	NULL
G.	NULL
H.	NULL
Goodwin	NULL
.	NULL

1986	NULL
.	NULL

Characterization	NULL
of	NULL
chicken	NULL
erythroid	NULL
nuclear	NULL
proteins	NULL
which	NULL
bind	NULL
to	NULL
the	NULL
nuclease	NULL
hypersensitive	NULL
regions	NULL
upstream	NULL
of	NULL
the	NULL
*-	NULL
and	NULL
-globin	NULL
genes	NULL
.	NULL

Nucleic	NULL
Acids	NULL
Res	NULL
.	NULL

14:7675-7693	NULL
.	NULL

Rosen	NULL
,	NULL
C.	NULL
A.	NULL
,	NULL
J.	NULL
G.	NULL
Sodroski	NULL
,	NULL
and	NULL
W.	NULL
A.	NULL
Haseltine	NULL
.	NULL

1985	NULL
.	NULL

The	NULL
location	NULL
of	NULL
cis-acting	NULL
regulatory	NULL
sequences	NULL
in	NULL
the	NULL
human	NULL
T	NULL
cell	NULL
lymphotropic	NULL
virus	NULL
type	NULL
III	NULL
(	NULL
HTLV-III/LAV	NULL
)	NULL
long	NULL
terminal	NULL
repeat	NULL
.	NULL

Cell	NULL
41:813-823	NULL
.	NULL

Shaw	NULL
,	NULL
J.-P.	NULL
,	NULL
P.	NULL
J.	NULL
Utz	NULL
,	NULL
D.	NULL
B.	NULL
Durand	NULL
,	NULL
J.	NULL
J.	NULL
Toole	NULL
,	NULL
E.	NULL
A.	NULL
Emmel	NULL
,	NULL
and	NULL
G.	NULL
R.	NULL
Crabtree	NULL
.	NULL

1988	NULL
.	NULL

Identification	NULL
of	NULL
a	NULL
putative	NULL
regulator	NULL
of	NULL
early	NULL
T	NULL
cell	NULL
activation	NULL
genes	NULL
.	NULL

Science	NULL
241:202-205	NULL
.	NULL

Sickevitz	NULL
,	NULL
M.	NULL
,	NULL
S.	NULL
F.	NULL
Josephs	NULL
,	NULL
M.	NULL
Dukovich	NULL
,	NULL
N.	NULL
Peffer	NULL
,	NULL
F.	NULL
Wong-Staal	NULL
,	NULL
and	NULL
W.	NULL
C.	NULL
Greene	NULL
.	NULL

1987	NULL
.	NULL

Activation	NULL
of	NULL
the	NULL
HIV-1	NULL
LTR	NULL
by	NULL
T	NULL
cell	NULL
mitogens	NULL
and	NULL
the	NULL
trans-activator	NULL
protein	NULL
of	NULL
HTLV-1	NULL
.	NULL

Science	NULL
238:1575-1578	NULL
.	NULL

Smith	NULL
,	NULL
M.	NULL
R.	NULL
,	NULL
and	NULL
W.	NULL
C.	NULL
Greene	NULL
.	NULL

1989	NULL
.	NULL

The	NULL
same	NULL
50-kDa	NULL
cellular	NULL
protein	NULL
binds	NULL
to	NULL
the	NULL
negative	NULL
regulatory	NULL
elements	NULL
of	NULL
the	NULL
interleukin-2	NULL
receptor	NULL
o-chain	NULL
gene	NULL
and	NULL
the	NULL
HIV-1	NULL
LTR	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
86:8526-8530	NULL
.	NULL

Tsai	NULL
,	NULL
S.	NULL
Y.	NULL
,	NULL
D.	NULL
J.	NULL
Carlstedt	NULL
,	NULL
N.	NULL
L.	NULL
Weigel	NULL
,	NULL
K.	NULL
Dahlman	NULL
,	NULL
J	NULL
.	NULL

A.	NULL
Gustafsson	NULL
,	NULL
M.	NULL
J.	NULL
Tsai	NULL
,	NULL
and	NULL
B.	NULL
W.	NULL
O'Malley	NULL
.	NULL

1988	NULL
.	NULL

Molecular	NULL
interactions	NULL
of	NULL
steroid	NULL
hormone	NULL
receptor	NULL
with	NULL
its	NULL
enhancer	NULL
element	NULL
:	NULL
evidence	NULL
for	NULL
receptor	NULL
dimer	NULL
formation	NULL
.	NULL

Cell	NULL
55:361-369	NULL
.	NULL

